What is mTilda?
mTilda specializes in developing a comprehensive Histocompatibility and Immunogenics (HLA) laboratory information management system (LIMS) designed for enterprise-level deployment. The platform offers a suite of scalable, HLA-specific modules that manage specimen workflow, patient and data management, inventory control, reagent vendor connectivity, and institutional EMR/LIS interoperability. Founded in 2000, mTilda's software is engineered to provide customizable reporting capabilities, addressing the complex needs of modern clinical laboratories. Its focus on interoperability and data management positions it as a key player in the health informatics and laboratory automation markets.
How much funding has mTilda raised?
mTilda has raised a total of $750K across 1 funding round:
Other Financing Round
$750K
Other Financing Round (2021): $750K with participation from Golden Section Venture Capital
Key Investors in mTilda
Golden Section Venture Capital
Golden Section Venture Capital is a venture capital firm known for partnering with entrepreneurs to build companies, likely focusing on technology and innovation.
What's next for mTilda?
The recent major strategic investment into mTilda signals a strong validation of its market position and future growth potential. This capital infusion is expected to fuel the company's expansion initiatives, potentially involving further development of its core LIMS platform, enhancement of its interoperability features with electronic health records, and broadening its market reach. As mTilda continues its trajectory, it is poised to solidify its standing as a leader in specialized laboratory information systems, driving innovation in immunogenetics and histocompatibility testing through strategic capital deployment and technological advancement.
See full mTilda company page
